Kyung Bo Kim is an Wertheim Medicine researcher based at the Florida International University Center for Translational Science in Port Saint Lucie, Florida. His research focuses on the intersection of chemistry and biology, emphasizing developing small molecules that target the ubiquitin-proteasome pathway. These molecules aim to uncover pathophysiological processes or offer potential treatments for human diseases. The Kim Lab is exploring using proteasome inhibitors to treat incurable diseases, including neurodegenerative diseases and cancers.
Before joining FIU, Kim was a faculty member in the Department of Pharmaceutical Sciences at the University of Kentucky College of Pharmacy.
Research Grants
- NIH R01 AG073122, Immunoproteasome inhibitors for the treatment of Alzheimer's disease The goal is to develop macrocyclic peptide epoxyketone-based drugs to alleviate cognitive deficits in Alzheimer's Disease patients independently of amyloid deposits and tau polymerization.
- 2024 FIU Medicine/Baptist Health Pilot Project Grant (AWD# 18179), Development of proteasome inhibitors for the treatment of glioblastoma The goal is to develop brain-permeable proteasome inhibitors for treating glioblastoma.
Research Interests
- Pharmacological intervention of Alzheimer's disease, Parkinson's disease, cancer (multiple myeloma), and inflammatory bowel disease.
- Mechanistic understanding of how the immunoproteasome modulates disease processes.
See research publications and more on FIU Discovery.
Education
- Postdoctoral training, Yale University, New Haven, CT
- Ph.D., Biochemistry, Ohio State University, Columbus, OH
- MS, Organic Chemistry, Pohang University of Science and Technology, Korea
- BS, Biochemistry, Yonsei University, Korea